Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading cause of cancer related death. Although the mortality rate of CRC is decreasing, finding novel targets for its therapy remains urgent. Carboxypeptidase E (CPE), a member of the pro-protein convertases, which are involved in the maturation of protein precursors, has recently been reported as elevated in many types of cancer. However, its role and mechanisms in tumor progression are poorly understood. »
09/05/13

The aim of this study was to investigate the differential expression of markers related to metabolic, mitochondrial, and autophagy status in different molecular subtypes of breast cancer. »
09/10/13

The prognosis of pancreatic cancer (PC) is one of the poorest among all cancers, due largely to the lack of methods for screening and early detection. New biomarkers for identifying high-risk or early-stage subjects could significantly impact PC mortality. The goal of this study was to find metabolic biomarkers associated with PC by using a comprehensive metabolomics technology to compare serum profiles of PC patients to healthy control subjects. »
09/12/13

Phase I/II clinical trials with these agents should include further pharmacodynamic endpoints »
02/25/13

Role for PI3'-kinase signaling in rate of lung tumor growth »
09/11/13

EpCAM signalling pathway correlated significantly with various clinico-pathological features of gastric cancer »
02/24/13

FHL2 a cell cycle and growth modulator inhibits apoptosis in colon cancer cells. »
06/24/13

Methylated miRNAs may provide putative markers to assess the presence of (pre)cancerous cervical lesions »
01/16/13

In developed countries, 40% of breast cancer patients are >65 years of age at diagnosis, of whom 16% additionally suffer from diabetes. The aim of this study was to assess the impact of diabetes on relapse-free period (RFP) and overall mortality in elderly breast cancer patients. »
09/13/13

Triple-negative breast cancer (TNBC) accounts for 10-20% of newly diagnosed invasive breast cancer. Finding effective targets for chemotherapy-resistant TNBC has proven difficult in part because of TNBC's molecular heterogeneity. We have previously reported that, likely because of GR's anti-apoptotic activity in ER-negative breast epithelial and cancer cells, high glucocorticoid receptor (GR) expression/activity in early-stage TNBC significantly correlates with chemotherapy-resistance and increased recurrence. We hypothesized that pre-treatment with mifepristone, a (GR)-antagonist, would potentiate the efficacy of chemotherapy in GR+ TNBC by inhibiting GR's anti-apoptotic signaling pathways and increasing the cytotoxic efficiency of chemotherapy. »
09/11/13